Combination of mitochondria impairment and inflammation blockade to combat metastasis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Mitochondria impairment is a promising anti-metastasis strategy.
• Existing mitochondria-targeting therapies face challenges in efficiency, drug leakage, and release.
• Tumor microenvironment (TME) inflammation and poor in vivo application hinder therapeutic efficacy.

Purpose of the Study:

• To develop an advanced drug delivery system for enhanced mitochondria targeting and on-demand drug release.
• To overcome limitations of in vivo application and address the inflammatory TME.
• To improve the suppression of primary tumor growth and distant metastasis.

Main Methods:

• Constructed an N-(2-hydroxypropyl) methacrylamide (HPMA) polymer-based cationic system for mitochondria targeting.
• Designed a nanocomposite (PDT-NCs) by combining cationic HPMA polymer and anionic hyaluronic acid for prolonged circulation and tumor targeting.
• Fabricated celecoxib-loaded liposomes (Lip-Cel) to alleviate TME inflammation and downregulate metastasis factors.

Main Results:

• The developed system demonstrated efficient mitochondria targeting and reactive oxygen species-triggered drug release.
• The combined PDT-NCs and Lip-Cel significantly suppressed primary tumor growth.
• A drastic improvement was observed in the suppression of distant lung metastasis.

Conclusions:

• The novel nanocomposite and liposome system effectively addresses challenges in mitochondria-targeting therapy.
• Simultaneous blockade of mitochondria dysfunction and tumor inflammation offers a potent strategy against metastatic tumors.
• This approach provides a generalizable framework for developing advanced anti-cancer therapeutics.